Drugs / TGplPTH1-34
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04294004 | Aug 2020 → Jul 2024 | lumbar disk degenerative disorder | Kuros Biosurgery AG | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-27 | Kuros Biosurgery AG | Results Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA kurosbio.com ↗
In the STRUCTURE trial, Fibrin-PTH, while demonstrating excellent clinical outcomes, showed fusion rates comparable to autograft in the less challenging interbody space. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-27 | Kuros Biosurgery AG | Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA kurosbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGplPTH1-34 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04294004 ↗ |
| Route | Other | “TGplPTH1-34 within a fibrin matrix applied within and around a polyetheretherketone (PEEK) intervertebral cage” NCT04294004 ↗ |